HC Wainwright Issues Negative Estimate for Balchem Earnings

Balchem Co. (NASDAQ:BCPC) – Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Balchem in a research report issued on Monday, February 24th. HC Wainwright analyst R. Selvaraju now expects that the basic materials company will post earnings per share of $0.99 for the quarter, down from their previous estimate of $1.06. HC Wainwright has a “Buy” rating and a $190.00 price objective on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share. HC Wainwright also issued estimates for Balchem’s Q2 2025 earnings at $1.03 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.12 EPS, FY2025 earnings at $4.22 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.20 EPS and FY2026 earnings at $4.71 EPS.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.08). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The business had revenue of $240.00 million for the quarter, compared to analysts’ expectations of $239.96 million.

Separately, StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Tuesday.

Balchem Trading Up 4.8 %

Shares of Balchem stock opened at $173.59 on Wednesday. The stock has a fifty day moving average price of $162.01 and a 200-day moving average price of $169.44. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. The firm has a market cap of $5.64 billion, a PE ratio of 44.17, a P/E/G ratio of 4.41 and a beta of 0.69. Balchem has a 1 year low of $137.69 and a 1 year high of $186.03.

Institutional Trading of Balchem

A number of large investors have recently bought and sold shares of BCPC. Covestor Ltd grew its stake in shares of Balchem by 93.8% during the 4th quarter. Covestor Ltd now owns 157 shares of the basic materials company’s stock worth $26,000 after acquiring an additional 76 shares during the period. Westside Investment Management Inc. bought a new stake in Balchem in the 3rd quarter valued at about $27,000. R Squared Ltd purchased a new stake in Balchem during the fourth quarter valued at about $29,000. Federated Hermes Inc. bought a new position in Balchem during the fourth quarter worth about $33,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Balchem in the third quarter worth about $35,000. 87.91% of the stock is owned by hedge funds and other institutional investors.

Balchem Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Friday, January 17th. Investors of record on Thursday, December 26th were paid a $0.87 dividend. This is an increase from Balchem’s previous annual dividend of $0.79. The ex-dividend date was Thursday, December 26th. This represents a yield of 0.4%. Balchem’s dividend payout ratio is presently 22.14%.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.